ArticleCancer medicine2022

Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.

Dominik A Barth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.